ophthalmology

News

Roche set to file ophthalmology drug faricimab in DME

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the in

News

Novartis signs ophthalmology AI deal with RetinAI

Novartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial intelligence (AI) tools to support ophthalmology and digital health pro

News

Janssen adds Hemera's AMD gene therapy to pipeline

Johnson & Johnson’s pharma unit Janssen has bought rights to an investigational gene therapy for a severe form age-related macular degeneration from specialist biotech Hemera Bioscience

News

MyTherapy Novartis - See What's Next (002)

Novartis taps smartpatient for app to support wet AMD patien...

German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet age-related macular degeneration (AMD), a leading cause of blindness.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA begins review of Samsung Bioepis/Biogen's Lucentis biosi...

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen

News

Novartis keeps a close eye on gene therapy with Vedere Bio b...

Already a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 million deal that builds its position in inherited eye diseases that can lead to blindness.

Roche set to file ophthalmology drug faricimab in DME

Novartis signs ophthalmology AI deal with RetinAI

Janssen adds Hemera's AMD gene therapy to pipeline

Novartis taps smartpatient for app to support wet AMD patien...

FDA begins review of Samsung Bioepis/Biogen's Lucentis biosi...

Novartis keeps a close eye on gene therapy with Vedere Bio b...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

ophthalmology

Editor's Picks